Updated on 27 September 2013
He also highlighted the accomplishments of the company in the last two years, that would prevent it from being barred from the US market due to the controversies.
"In the last two years, Ranbaxy has launched several products in the US including Atorvastatin, Absorica, Desvenlafaxine, Cevimeline (Evoxac) and continues to market to the US Federal Government. In India, we launched the first New Chemical Entity (NCE), SynriamTM for the treatment of malaria and we are now working towards taking this product to other developing countries. In the emerging markets of Africa, Latin America, CIS and Asia, Ranbaxy continues to provide a wide range of World Health Organization prequalified (WHO PQ) ARVs in addition to supplying high quality generic medicines. About 1 million patients worldwide use Ranbaxy's ARV products for their daily treatment needs," he added
Mr Sawhney has reassured in his letter, "All Ranbaxy products being supplied in India and globally are safe and efficacious. Ranbaxy remains strongly committed to providing high quality, affordable drugs to patients in India and other parts of the world. We are guided by our philosophy of ‘Quality and Patients First', and will uphold the highest quality standards that patients, prescribers, government and all other stakeholders expect from Ranbaxy."